Clinical Study Enrollment Completed for UroActive Device
Researchers have finished enrolling 140 patients for a clinical trial of the electronic artificial urinary sphincter.
Updated on Sept. 20, 2026 in Stroke
Live Poll
Would you trust a medical device you can control with a remote for your health care?
Clinical enrollment has concluded for the UroActive artificial urinary sphincter study. The device utilizes a remote-controlled implant to manage urinary flow, aiming to assist those suffering from chronic incontinence.
Why it matters
The system was developed to solve patient aversion to the manual manipulation required by older sphincter devices. It offers an electronic alternative for individuals experiencing chronic urinary issues following prostate cancer surgery.
A prior first-in-human trial involving six patients in France demonstrated a reduction in daily pad counts from 3.7 to 1.0 at one year. The implant features an electronic battery rated for 10 years of continuous use.
The players
UroActive
This is a medical device company developing electronic artificial urinary sphincter technology for patients with chronic incontinence.
The details
The UroActive system features a metal implant with an electronic chip that is surgically placed in the abdomen. Patients use an external remote control to activate and adjust pressure levels based on their daily activity.
Timeline
Enrollment for the 140-patient study was completed in 2026.
Initial results from the SOPHIA2 study are expected in 2027.
The Big Picture
This development follows the standardized progression of the SOPHIA2 clinical study, which serves as a critical phase for validating new medical device interventions. The research reflects a shift toward electronic, remote-managed implants to improve long-term patient compliance.
For patients suffering from chronic incontinence following prostate cancer surgery, this device offers a potential alternative to traditional manual-manipulation sphincters. The remote-controlled system aims to improve quality of life by simplifying the management of urinary flow.
The takeaway
This technology highlights a growing movement toward integrating electronic controls into traditional urological implants. Patients facing chronic post-surgical incontinence should monitor future trial results for updates on accessibility and potential clinical approval.
What happens next
Initial results from the SOPHIA2 clinical study are scheduled for release in 2027.
Further reading
For more information on the latest developments in medical technology and interventions, visit the Stroke section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Would you trust a medical device you can control with a remote for your health care?
